Blood-stage malaria vaccines - Recent progress and future challenges

Annals of Tropical Medicine and Parasitology

Volumn 104, Issue 3, 2010, Pages 189-211

  Goodman, A L ^a   Draper, S J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGATOLIMOD; ALUMINUM HYDROXIDE; APICAL MEMBRANE ANTIGEN 1; AS 01; AS 01 A; AS 01 B; AS 01A; AS 01B; AS 02; CIRCUMSPOROZOITE PROTEIN; ERYTHROCYTE BINDING ANTIGEN; GLUTAMATE RICH PROTEIN; IMMUNOLOGICAL ADJUVANT; MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 1; MEROZOITE SURFACE PROTEIN 3; MEROZOITE SURFACE PROTEIN 9; MONTANIDE ISA 720; PARASITE ANTIGEN; PEPTIDE VACCINE; PFS25 ANTIGEN; RECOMBINANT VACCINE; RHOPTRY PROTEIN; RING INFECTED ERYTHROCYTE SURFACE ANTIGEN; SERINE REPEAT ANTIGEN; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; PROTOZOAL PROTEIN;

ADULT; ANTIBODY TITER; CHILD; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; HUMAN; IMMUNOASSAY; IMMUNOGENICITY; MALARIA FALCIPARUM; NONHUMAN; PARASITE DEVELOPMENT; PLASMODIUM FALCIPARUM; REVIEW; VACCINATION; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; MALARIA, FALCIPARUM; PROCEDURES;

PLASMODIUM FALCIPARUM;

ANTIGENS, PROTOZOAN; CLINICAL TRIALS AS TOPIC; HUMANS; MALARIA VACCINES; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; VACCINATION;

EID: 77952862926     PISSN: 00034983     EISSN: 13648594     Source Type: Journal    
DOI: 10.1179/136485910X12647085215534     Document Type: Review

References (138)

1. Abdulla, S., Oberholzer, R., Juma, O., Kubhoja, S., Machera, F., Membi, C., Omari, S., Urassa, A., Mshinda, H., Jumanne, A., Salim, N., Shomari, M., Aebi, T., Schellenberg, D. M., Carter, T., Villafana, T., Demoitié, M.-A., Dubois, M.-C., Leach, A., Lievens, M., Vekemans, J., Cohen, J., Ballou, W. R. & Tanner, M. (2008). Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants. New England Journal of Medicine, 359, 2533-2544.
2. Alonso, P. L., Sacarlal, J., Aponte, J. J., Leach, A., Macete, E., Milman, J., Mandomando, I., Spiessens, B., Guinovart, C., Espasa, M., Bassat, Q., Aide, P., Ofori-Anyinam, O., Navia, M. M., Corachan, S., Ceuppens, M., Dubois, M.-C., Demoitié, M.-A., Dubovsky, F., Menendez, C., Tornieporth, N., Ballou, W. R., Thompson, R. & Cohen, J. (2004). Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet, 364, 1411-1420.
3. Alonso, P. L., Sacarlal, J., Aponte, J. J., Leach, A., Macete, E., Aide, P., Sigauque, B., Milman, J., Mandomando, I., Bassat, Q., Guinovart, C., Espasa, M., Corachan, S., Lievens, M., Navia, M. M., Dubois, M.-C., Menendez, C., Dubovsky, F., Cohen, J., Thompson, R. & Ballou, W. R. (2005). Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet, 366, 2012-2018.
4. Arévalo-Herrera, M., Chitnis, C. & Herrera, S. (2010). Current status of Plasmodium vivax vaccine. Human Vaccines, in press.
5. Atmar, R. L. & Keitel, W. A. (2009). Adjuvants for pandemic influenza vaccines. Current Topics in Microbiology and Immunology, 333, 323-344.
6. Audran, R., Cachat, M., Lurati, F., Soe, S., Leroy, O., Corradin, G., Druilhe, P. & Spertini, F. (2005). Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen. Infection and Immunity, 73, 8017-8026.
7. Ballou, W. R. (2009). The development of the RTS,S malaria vaccine candidate: challenges and lessons. Parasite Immunology, 31, 492-500.
8. Ballou, W. R., Arévalo-Herrera, M., Carucci, D., Richie, T. L., Corradin, G., Diggs, C., Druilhe, P., Giersing, B. K., Saul, A., Heppner, D. G., Kester, K. E., Lanar, D. E., Lyon, J., Hill, A. V. S., Pan, W. & Cohen, J. D. (2004). Update on the clinical development of candidate malaria vaccines. American Journal of Tropical Medicine and Hygiene, 71, 239-247.
9. Bejon, P., Andrews, L., Andersen, R. F., Dunachie, S., Webster, D., Walther, M., Gilbert, S. C., Peto, T. & Hill, A. V. S. (2005). Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites. Journal of Infectious Diseases, 191, 619-626.
10. Bejon, P., Lusingu, J., Olotu, A., Leach, A., Lievens, M., Vekemans, J., Mshamu, S., Lang, T., Gould, J., Dubois, M.-C., Demoitié, M.-A., Stallaert, J.-F., Vansadia, P., Carter, T., Njuguna, P., Awuondo, K. O., Malabeja, A., Abdul, O., Gesase, S., Mturi, N., Drakeley, C. J., Savarese, B., Villafana, T., Ballou, W. R., Cohen, J., Riley, E. M., Lemnge, M. M., Marsh, K. & von Seidlein, L. (2008). Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. New England Journal of Medicine, 359, 2521-2532.
11. Belnoue, E., Voza, T., Costa, F. T. M., Grüner, A. C., Mauduit, M., Rosa, D. S., Depinay, N., Kayibanda, M., Vigário, A. M., Mazier, D., Snounou, G., Sinnis, P. & Rénia, L. (2008). Vaccination with live Plasmodium yoelii blood stage parasites under chloroquine cover induces cross-stage immunity against malaria liver stage. Journal of Immunology, 181, 8552-8558.
12. Bergmann-Leitner, E. S., Duncan, E. H., Mullen, G. E., Burge, J. R., Khan, F., Long, C. A., Angov, E. & Lyon, J. A. (2006). Critical evaluation of different methods for measuring the functional activity of antibodies against malaria blood stage antigens. American Journal of Tropical Medicine and Hygiene, 75, 437-442.
13. Blanchard Rohner, G., Snape, M. D., Kelly, D. F., John, T., Morant, A., Yu, L.-M., Borkowski, A., Ceddia, F., Borrow, R., Siegrist, C.-A. & Pollard, A. J. (2008). The magnitude of the antibody and memory B cell responses during priming with a protein-polysaccharide conjugate vaccine in human infants is associated with the persistence of antibody and the intensity of booster response. Journal of Immunology, 180, 2165-2173.
14. Bouharoun-Tayoun, H., Attanath, P., Sabchareon, A., Chongsuphajaisiddhi, T. & Druilhe, P. (1990). Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes. Journal of Experimental Medicine, 172, 1633-1641.
15. Bull, P. C., Lowe, B. S., Kortok, M., Molyneux, C. S., Newbold, C. I. & Marsh, K. (1998). Parasite antigens on the infected red cell surface are targets for naturally acquired immunity to malaria. Nature Medicine, 4, 358-360.
16. Butler, D. (2009). Initiative targets malaria eradication. Nature, 462, 19.
17. Carvalho, L. J. M., Alves, F. A., Bianco Jr, C., Oliveira, S. G., Zanini, G. M., Soe, S., Druilhe, P., Theisen, M., Muniz, J. A. P. C. & Daniel-Ribeiro, C. T. (2005). Immunization of Saimiri sciureus monkeys with a recombinant hybrid protein derived from the Plasmodium falciparum antigen glutamate-rich protein and merozoite surface protein 3 can induce partial protection with Freund and Montanide ISA720 adjuvants. Clinical and Diagnostic Laboratory Immunology, 12, 242-248.
18. Chowdhury, D. R., Angov, E., Kariuki, T. & Kumar, N. (2009). A potent malaria transmission blocking vaccine based on codon harmonized full length Pfs48/45 expressed in Escherichia coli. PLoS One, 4, e6352.
19. Coler, R. N., Carter, D., Friede, M. & Reed, S. G. (2009). Adjuvants for malaria vaccines. Parasite Immunology, 31, 520-528.
20. Coppel, R. L. (2009). Vaccinating with the genome: a Sisyphean task? Trends in Parasitology, 25, 205-212.
21. Crompton, P. D., Mircetic, M., Weiss, G., Baughman, A., Huang, C.-Y., Topham, D. J., Treanor, J. J., Sanz, I., Lee, F. E.-H., Durbin, A. P., Miura, K., Narum, D. L., Ellis, R. D., Malkin, E., Mullen, G. E. D., Miller, L. H., Martin, L. B. & Pierce, S. K. (2009). The TLR9 ligand CpG promotes the acquisition of Plasmodium falciparum-specific memory B cells in malaria-naive individuals. Journal of Immunology, 182, 3318-3326.
22. Crompton, P. D., Miura, K., Traore, B., Kayentao, K., Ongoiba, A., Weiss, G., Doumbo, S., Doumtabe, D., Kone, Y., Huang, C. Y., Doumbo, O. K., Miller, L. H., Long, C. A. & Pierce, S. K. (2010). In vitro growth-inhibitory activity and malaria risk in a cohort study in Mali. Infection and Immunity, 78, 737-745.
23. De Koning-Ward, T. F., O'Donnell, R. A., Drew, D. R., Thomson, R., Speed, T. P. & Crabb, B. S. (2003). A new rodent model to assess blood stage immunity to the Plasmodium falciparum antigen merozoite surface protein 119 reveals a protective role for invasion inhibitory antibodies. Journal of Immunology, 198, 869-875.
24. Dicko, A., Diemert, D. J., Sagara, I., Sogoba, M., Niambele, M. B., Assadou, M. H., Guindo, O., Kamate, B., Baby, M., Sissoko, M., Malkin, E. M., Fay, M. P., Thera, M. A., Miura, K., Dolo, A., Diallo, D. A., Mullen, G. E., Long, C. A., Saul, A., Doumbo, O. & Miller, L. H. (2007). Impact of a Plasmodium falciparum AMA1 vaccine on antibody responses in adult Malians. PLoS One, 2, e1045.
25. Dicko, A., Sagara, I., Ellis, R. D., Miura, K., Guindo, O., Kamate, B., Sogoba, M., Niambele, M. B., Sissoko, M., Baby, M., Dolo, A., Mullen, G. E., Fay, M. P., Pierce, M., Diallo, D. A., Saul, A., Miller, L. H. & Doumbo, O. K. (2008). Phase 1 study of a combination AMA1 blood stage malaria vaccine in Malian children. PLoS One, 3, e1563.
26. Dodoo, D., Aikins, A., Kusi, K. A., Lamptey, H., Remarque, E., Milligan, P., Bosomprah, S., Chilengi, R., Osei, Y. D., Akanmori, B. D. & Theisen, M. (2008). Cohort study of the association of antibody levels to AMA1, MSP119, MSP3 and GLURP with protection from clinical malaria in Ghanaian children. Malaria Journal, 7, 142.
27. Doolan, D. L., Southwood, S., Freilich, D. A., Sidney, J., Graber, N. L., Shatney, L., Bebris, L., Florens, L., Dobano, C., Witney, A. A., Appella, E., Hoffman, S. L., Yates III, J. R., Carucci, D. J. & Sette, A. (2003). Identification of Plasmodium falciparum antigens by antigenic analysis of genomic and proteomic data. Proceedings of the National Academy of Sciences of the United States of America, 100, 9952-9957.
28. Doolan, D. L., Mu, Y., Unal, B., Sundaresh, S., Hirst, S., Valdez, C., Randall, A., Molina, D., Liang, X., Freilich, D. A., Oloo, J. A., Blair, P. L., Aguiar, J. C., Baldi, P., Davies, D. H. & Felgner, P. L. (2008). Profiling humoral immune responses to P. falciparum infection with protein microarrays. Proteomics, 8, 4680-4694.
29. Dorfman, J. R., Bejon, P., Ndungu, F. M., Langhorne, J., Kortok, M. M., Lowe, B. S., Mwangi, T. W., Williams, T. N. & Marsh, K. (2005). B cell memory to 3 Plasmodium falciparum blood-stage antigens in a malaria-endemic area. Journal of Infectious Diseases, 191, 1623-1630.
30. Draper, S. J. & Heeney, J. L. (2010). Viruses as vaccine vectors for infectious diseases and cancer. Nature Reviews, Microbiology, 8, 62-73.
31. Draper, S. J., Moore, A. C., Goodman, A. L., Long, C. A., Holder, A. A., Gilbert, S. C., Hill, F. & Hill, A. V. S. (2008). Effective induction of high-titer antibodies by viral vector vaccines. Nature Medicine, 14, 819-821.
32. Draper, S. J., Goodman, A. L., Biswas, S., Forbes, E. K., Moore, A. C., Gilbert, S. C. & Hill, A. V. S. (2009). Recombinant viral vaccines expressing merozoite surface protein-1 induce antibody- and T cellmediated multistage protection against malaria. Cell Host and Microbe, 5, 95-105.
33. Dunachie, S. J., Walther, M., Epstein, J. E., Keating, S., Berthoud, T., Andrews, L., Andersen, R. F., Bejon, P., Goonetilleke, N., Poulton, I., Webster, D. P., Butcher, G., Watkins, K., Sinden, R. E., Levine, G. L., Richie, T. L., Schneider, J., Kaslow, D., Gilbert, S. C., Carucci, D. J. & Hill, A. V. S. (2006). A DNA prime-modified vaccinia virus Ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge. Infection and Immunity, 74, 5933-5942.
34. Dutta, S., Haynes, J. D., Barbosa, A., Ware, L. A., Snavely, J. D., Moch, J. K., Thomas, A. W. & Lanar, D. E. (2005). Mode of action of invasion-inhibitory antibodies directed against apical membrane antigen 1 of Plasmodium falciparum. Infection and Immunity, 73, 2116-2122.
35. Dutta, S., Sullivan, J. S., Grady, K. K., Haynes, J. D., Komisar, J., Batchelor, A. H., Soisson, L., Diggs, C. L., Heppner, D. G., Lanar, D. E., Collins, W. E. & Barnwell, J. W. (2009). High antibody titer against apical membrane antigen-1 is required to protect against malaria in the Aotus model. PLoS One, 4, e8138.
36. Edstein, M. D., Kotecka, B. M., Anderson, K. L., Pombo, D. J., Kyle, D. E., Rieckmann, K. H. & Good, M. F. (2005). Lengthy antimalarial activity of atovaquone in human plasma following atovaquone-proguanil administration. Antimicrobial Agents and Chemotherapy, 49, 4421-4422.
37. Egan, A., Waterfall, M., Pinder, M., Holder, A. & Riley, E. (1997). Characterization of human T- and B-cell epitopes in the C terminus of Plasmodium falciparum merozoite surface protein 1: evidence for poor T-cell recognition of polypeptides with numerous disulfide bonds. Infection and Immunity, 65, 3024-3031.
38. Ellis, R. D., Mullen, G. E. D., Pierce, M., Martin, L. B., Miura, K., Fay, M. P., Long, C. A., Shaffer, D., Saul, A., Miller, L. H. & Durbin, A. P. (2009). A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel with CPG 7909, using two different formulations and dosing intervals. Vaccine, 27, 4104-4109.
39. Ellis, R. D., Martin, L. B., Shaffer, D., Long, C. A., Miura, K., Fay, M. P., Narum, D. L., Zhu, D., Mullen, G. E. D., Mahanty, S., Miller, L. H. & Durbin, A. P. (2010). Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/ Alhydrogel with and without CPG 7909 in malaria naive adults. PLoS One, 5, e8787.
40. Esen, M., Kremsner, P. G., Schleucher, R., Gassler, M., Imoukhuede, E. B., Imbault, N., Leroy, O., Jepsen, S., Knudsen, B. W., Schumm, M., Knobloch, J., Theisen, M. & Mordmü ller, B. (2009). Safety and immunogenicity of GMZ2 - a MSP3-GLURP fusion protein malaria vaccine candidate. Vaccine, 27, 6862-6868.
41. Faber, B. W., Remarque, E. J., Morgan, W. D., Kocken, C. H. M., Holder, A. A. & Thomas, A. W. (2007). Malaria vaccine-related benefits of a single protein comprising Plasmodium falciparum apical membrane antigen 1 domains I and II fused to a modified form of the 19-kilodalton C-terminal fragment of merozoite surface protein 1. Infection and Immunity, 75, 5947-5955.
42. Fleit, H. B. & Kobasiuk, C. D. (1991). The human monocyte-like cell line THP-1 expresses Fc gamma RI and Fc gamma RII. Journal of Leukocyte Biology, 49, 556-565.
43. Freitas do Rosario, A. P., Muxel, S. M., Rodriguez-Malaga, S. M., Sardinha, L. R., Zago, C. A., Castillo-Mendez, S. I., Alvarez, J. M. & d'Imperio Lima, M. R. (2008). Gradual decline in malaria-specific memory T cell responses leads to failure to maintain long-term protective immunity to Plasmodium chabaudi AS despite persistence of B cell memory and circulating antibody. Journal of Immunology, 181, 8344-8355.
44. Gardner, M. J., Hall, N., Fung, E., White, O., Berriman, M., Hyman, R. W., Carlton, J. M., Pain, A., Nelson, K. E., Bowman, S., Paulsen, I. T., James, K., Eisen, J. A., Rutherford, K., Salzberg, S. L., Craig, A., Kyes, S., Chan, M.-S., Nene, V., Shallom, S. J., Suh, B., Peterson, J., Angiuoli, S., Pertea, M., Allen, J., Selengut, J., Haft, D., Mather, M. W., Vaidya, A. B., Martin, D. M., Fairlamb, A. H., Fraunholz, M. J., Roos, D. S., Ralph, S. A., McFadden, G. I., Cummings, L. M., Subramanian, G. M., Mungall, C., Venter, J. C., Carucci, D. J., Hoffman, S. L., Newbold, C., Davis, R. W., Fraser, C. M. & Barrell, B. (2002). Genome sequence of the human malaria parasite Plasmodium falciparum. Nature, 419, 498-511.
45. Genton, B., Al-Yaman, F., Anders, R., Saul, A., Brown, G., Pye, D., Irving, D. O., Briggs, W. R., Mai, A., Ginny, M., Adiguma, T., Rare, L., Giddy, A., Reber-Liske, R., Stuerchler, D. & Alpers, M. P. (2000). Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea. Vaccine, 18, 2504-2511.
46. Genton, B., Betuela, I., Felger, I., Al-Yaman, F., Anders, R. F., Saul, A., Rare, L., Baisor, M., Lorry, K., Brown, G. V., Pye, D., Irving, D. O., Smith, T. A., Beck, H.-P. & Alpers, M. P. (2002). A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a Phase 1-2b trial in Papua New Guinea. Journal of Infectious Diseases, 185, 820-827.
47. Genton, B., Al-Yaman, F., Betuela, I., Anders, R. F., Saul, A., Baea, K., Mellombo, M., Taraika, J., Brown, G. V., Pye, D., Irving, D. O., Felger, I., Beck, H. P., Smith, T. A. & Alpers, M. P. (2003). Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean children. Vaccine, 22, 30-41.
48. Gikonyo, C., Bejon, P., Marsh, V. & Molyneux, S. (2008). Taking social relationships seriously: lessons learned from the informed consent practices of a vaccine trial on the Kenyan coast. Social Science and Medicine, 67, 708-720.
49. Graves, P. & Gelband, H. (2006). Vaccines for Preventing Malaria (SPf66). Cochrane Database of Systematic Reviews 2006. Art. No. CD005966. Chichester, U.K.: John Wiley & Sons.
50. Hermsen, C. C., de Vlas, S. J., van Gemert, G. J., Telgt, D. S. C., Verhage, D. F. & Sauerwein, R. W. (2004). Testing vaccines in human experimental malaria: statistical analysis of parasitemia measured by a quantitative real-time polymerase chain reaction. American Journal of Tropical Medicine and Hygiene, 71, 196-201.
51. Hill, A. V. S. (2006). Pre-erythrocytic malaria vaccines: towards greater efficacy. Nature Reviews, Immunology, 6, 21-32.
52. Hill, A. V. S., Reyes-Sandoval, A., O'Hara, G., Ewer, K., Lawrie, A., Goodman, A., Nicosia, A., Folgori, A., Colloca, S., Cortese, R., Gilbert, S. C. & Draper, S. J. (2010). Prime-boost vectored malaria vaccines: progress and prospects. Human Vaccines, in press.
53. Hirunpetcharat, C., Tian, J. H., Kaslow, D. C., van Rooijen, N., Kumar, S., Berzofsky, J. A., Miller, L. H. & Good, M. F. (1997). Complete protective immunity induced in mice by immunization with the 19-kilodalton carboxyl-terminal fragment of the merozoite surface protein-1 (MSP1[19]) of Plasmodium yoelii expressed in Saccharomyces cerevisiae: correlation of protection with antigen-specific antibody titer, but not with effector CD4z T cells. Journal of Immunology, 159, 3400-3411.
54. Holder, A. A. (2009). The carboxy-terminus of merozoite surface protein 1: structure, specific antibodies and immunity to malaria. Parasitology, 136, 1445-1456.
55. Hu, J., Chen, Z., Gu, J., Wan, M., Shen, Q., Kieny, M. P., He, J., Li, Z., Zhang, Q., Reed, Z. H., Zhu, Y., Li, W., Cao, Y., Qu, L., Cao, Z., Wang, Q., Liu, H., Pan, X., Huang, X., Zhang, D., Xue, X. & Pan, W. (2008). Safety and immunogenicity of a malaria vaccine, Plasmodium falciparum AMA-1/MSP-1 chimeric protein formulated in montanide ISA 720 in healthy adults. PLoS One, 3, e1952.
56. Huaman, M. C., Martin, L. B., Malkin, E., Narum, D. L., Miller, L. H., Mahanty, S. & Long, C. A. (2008). Ex vivo cytokine and memory T cell responses to the 42-kDa fragment of Plasmodium falciparum merozoite surface protein-1 in vaccinated volunteers. Journal of Immunology, 180, 1451-1461.
57. Hviid, L. (2010). The role of Plasmodium falciparum variant surface antigens in protective immunity and vaccine development. Human Vaccines, in press.
58. Jafarshad, A., Dziegiel, M. H., Lundquist, R., Nielsen, L. K., Singh, S. & Druilhe, P. L. (2007). A novel antibody-dependent cellular cytotoxicity mechanism involved in defense against malaria requires costimulation of monocytes FcgammaRII and FcgammaRIII. Journal of Immunology, 178, 3099-3106.
59. Jones, T. R., Narum, D. L., Gozalo, A. S., Aguiar, J., Fuhrmann, S. R., Liang, H., Haynes, J. D., Moch, J. K., Lucas, C., Luu, T., Magill, A. J., Hoffman, S. L. & Sim, B. K. L. (2001). Protection of Aotus monkeys by Plasmodium falciparum EBA-175 region II DNA prime-protein boost immunization regimen. Journal of Infectious Diseases, 183, 303-312.
60. Kawabata, Y., Udono, H., Honma, K., Ueda, M., Mukae, H., Kadota, J., Kohno, S. & Yui, K. (2002). Merozoite surface protein 1-specific immune response is protective against exoerythrocytic forms of Plasmodium yoelii. Infection and Immunity, 70, 6075-6082.
61. Keitel, W. A., Kester, K. E., Atmar, R. L., White, A. C., Bond, N. H., Holland, C. A., Krzych, U., Palmer, D. R., Egan, A., Diggs, C., Ballou, W. R., Hall, B. F. & Kaslow, D. (1999). Phase I trial of two recombinant vaccines containing the 19 kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-1(19)) and T helper epitopes of tetanus toxoid. Vaccine, 18, 531-539.
62. Kleinschmidt, I., Schwabe, C., Benavente, L., Torrez, M., Ridl, F. C., Segura, J. L., Ehmer, P. & Nchama, G. N. (2009). Marked increase in child survival after four years of intensive malaria control. American Journal of Tropical Medicine and Hygiene, 80, 882-888.
63. Kumar, S., Yadava, A., Keister, D. B., Tian, J. H., Ohl, M., Perdue-Greenfield, K. A., Miller, L. H. & Kaslow, D. C. (1995). Immunogenicity and in vivo efficacy of recombinant Plasmodium falciparum merozoite surface protein-1 in Aotus monkeys. Molecular Medicine, 1, 325-332.
64. Kushwaha, A., Rao, P. P. L., Suresh, R. P. & Chauhan, V. S. (2001). Immunogenicity of recombinant fragments of Plasmodium falciparum acidic basic repeat antigen produced in Escherichia coli. Parasite Immunology, 23, 435-444.
65. Lawrence, G., Cheng, Q. Q., Reed, C., Taylor, D., Stowers, A., Cloonan, N., Rzepczyk, C., Smillie, A., Anderson, K., Pombo, D., Allworth, A., Eisen, D., Anders, R. & Saul, A. (2000). Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in nonimmune volunteers. Vaccine, 18, 1925-1931.
66. Lengeler, C. (2004). Insecticide-treated Bed Nets and Curtains for Preventing Malaria. The Cochrane Database of Systematic Reviews 2004. Art. No. CD000363. Chichester, U.K.: John Wiley & Sons.
67. Limbach, K. J. & Richie, T. L. (2009). Viral vectors in malaria vaccine development. Parasite Immunology, 31, 501-519.
68. Lopera-Mesa, T. M., Kushwaha, A., Mohmmed, A. & Chauhan, V. S. (2008). Plasmodium berghei merozoite surface protein-9: immunogenicity and protective efficacy using a homologous challenge model. Vaccine, 26, 1335-1343.
69. Lusingu, J. P., Gesase, S., Msham, S., Francis, F., Lemnge, M., Seth, M., Sembuche, S., Rutta, A., Minja, D., Segeja, M. D., Bosomprah, S., Cousens, S., Noor, R., Chilengi, R. & Druilhe, P. (2009). Satisfactory safety and immunogenicity of MSP3 malaria vaccine candidate in Tanzanian children aged 12-24 months. Malaria Journal, 8, 163.
70. Makobongo, M. O., Riding, G., Xu, H., Hirunpetcharat, C., Keough, D., de Jersey, J., Willadsen, P. & Good, M. F. (2003). The purine salvage enzyme hypoxanthine guanine xanthine phosphoribosyl transferase is a major target antigen for cell-mediated immunity to malaria. Proceedings of the National Academy of Sciences of the United States of America, 100, 2628-2633.
71. Malkin, E., Diemert, D. J., McArthur, J. H., Perreault, J. R., Miles, A. P., Giersing, B. K., Mullen, G. E., Orcutt, A., Muratova, O., Awkal, M., Zhou, H., Wang, J., Stowers, A., Long, C. A., Mahanty, S., Miller, L. H., Saul, A. & Durbin, A. P. (2005). Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria. Infection and Immunity, 73, 3677-3685.
72. Malkin, E., Long, C. A., Stowers, A. W., Zou, L., Singh, S., Macdonald, N. J., Narum, D. L., Miles, A. P., Orcutt, A. C., Muratova, O., Moretz, S. E., Zhou, H., Diouf, A., Fay, M., Tierney, E., Leese, P., Mahanty, S., Miller, L. H., Saul, A. & Martin, L. B. (2007). Phase 1 study of two merozoite surface protein 1 (MSP1(42)) vaccines for Plasmodium falciparum malaria. PLoS Clinical Trials, 2, e12.
73. Malkin, E., Hu, J., Li, Z., Chen, Z., Bi, X., Reed, Z., Dubovsky, F., Liu, J., Wang, Q., Pan, X., Chen, T., Giersing, B., Xu, Y., Kang, X., Gu, J., Shen, Q., Tucker, K., Tierney, E., Pan, W., Long, C. & Cao, Z. (2008). A Phase 1 trial of PfCP2.9: an AMA1/ MSP1 chimeric recombinant protein vaccine for Plasmodium falciparum malaria. Vaccine, 26, 6864-6873.
74. McIntosh, R. S., Shi, J., Jennings, R. M., Chappel, J. C., de Koning-Ward, T. F., Smith, T., Green, J., van Egmond, M., Leusen, J. H. W., Lazarou, M., van de Winkel, J., Jones, T. S., Crabb, B. S., Holder, A. A. & Pleass, R. J. (2007). The importance of human FcgammaRI in mediating protection to malaria. PLoS Pathogens, 3, e72.
75. Miura, K., Zhou, H., Diouf, A., Moretz, S. E., Fay, M. P., Miller, L. H., Martin, L. B., Pierce, M. A., Ellis, R. D., Mullen, G. E. D. & Long, C. A. (2009). Anti-apical-membrane-antigen-1 antibody is more effective than anti-42-kilodalton-merozoite-surface-protein-1 antibody in inhibiting Plasmodium falciparum growth, as determined by the in vitro growth inhibition assay. Clinical and Vaccine Immunology, 16, 963-968.
76. Mlambo, G. & Kumar, N. (2008). Transgenic rodent Plasmodium berghei parasites as tools for assessment of functional immunogenicity and optimization of human malaria vaccines. Eukaryotic Cell, 7, 1875-1879.
77. Mlambo, G., Maciel, J. & Kumar, N. (2008). Murine model for assessment of Plasmodium falciparum transmission-blocking vaccine using transgenic Plasmodium berghei parasites expressing the target antigen Pfs25. Infection and Immunity, 76, 2018-2024.
78. Moorthy, V. S., Diggs, C., Ferro, S., Good, M. F., Herrera, S., Hill, A. V., Imoukhuede, E. B., Kumar, S., Loucq, C., Marsh, K., Ockenhouse, C. F., Richie, T. L. & Sauerwein, R. W. (2009). Report of a consultation on the optimization of clinical challenge trials for evaluation of candidate blood stage malaria vaccines, 18-19 March 2009, Bethesda, MD, USA. Vaccine, 27, 5719-5725.
79. Mullen, G. E. D., Giersing, B. K., Ajose-Popoola, O., Davis, H. L., Kothe, C., Zhou, H., Aebig, J., Dobrescu, G., Saul, A. & Long, C. A. (2006). Enhancement of functional antibody responses to AMA1-C1/Alhydrogel, a Plasmodium falciparum malaria vaccine, with CpG oligodeoxynucleotide. Vaccine, 24, 2497-2505.
80. Mullen, G. E. D., Ellis, R. D., Miura, K., Malkin, E., Nolan, C., Hay, M., Fay, M. P., Saul, A., Zhu, D., Rausch, K., Moretz, S., Zhou, H., Long, C. A., Miller, L. H. & Treanor, J. (2008). Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria. PLoS One, 3, e2940.
81. Murhandarwati, E. E. H., Wang, L., Black, C. G., Nhan, D. H., Richie, T. L. & Coppel, R. L. (2009). Inhibitory antibodies specific for the 19-kilodalton fragment of merozoite surface protein 1 do not correlate with delayed appearance of infection with Plasmodium falciparum in semi-immune individuals in Vietnam. Infection and Immunity, 77, 4510-4517.
82. Murhandarwati, E. E. H., Wang, L., de Silva, H. D., Ma, C., Plebanski, M., Black, C. G. & Coppel, R. L. (2010). Growth-inhibitory antibodies are not necessary for protective immunity to malaria infection. Infection and Immunity, 78, 680-687.
83. Ndungu, F. M., Cadman, E. T., Coulcher, J., Nduati, E., Couper, E., Macdonald, D. W., Ng, D. & Langhorne, J. (2009). Functional memory B cells and long-lived plasma cells are generated after a single Plasmodium chabaudi infection in mice. PLoS Pathogens, 5, e1000690.
84. Nebie, I., Diarra, A., Ouedraogo, A., Tiono, A. B., Konate, A. T., Gansane, A., Soulama, I., Cousens, S., Leroy, O. & Sirima, S. B. (2009). Humoral and cell-mediated immunity to MSP3 peptides in adults immunized with MSP3 in malaria endemic area, Burkina Faso. Parasite Immunology, 31, 474-480.
85. O'Donnell, R. A., Saul, A., Cowman, A. F. & Crabb, B. S. (2000). Functional conservation of the malaria vaccine antigen MSP-119 across distantly related Plasmodium species. Nature Medicine, 6, 91-95.
86. Ockenhouse, C. F., Sun, P.-F., Lanar, D. E., Wellde, B. T., Hall, B. T., Kester, K., Stoute, J. A., Magill, A., Krzych, U., Farley, L., Wirtz, R. A., Sadoff, J. C., Kaslow, D. C., Kumar, S., Church, L. W. P., Crutcher, J. M., Wizel, B., Hoffman, S., Lalvani, A., Hill, A. V. S., Tine, J. A., Guito, K. P., de Taisne, C., Anders, R., Horii, T., Paoletti, E. & Ballou, W. R. (1998). Phase I/ IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. Journal of Infectious Diseases, 177, 1664-1673.
87. Ockenhouse, C. F., Angov, E., Kester, K. E., Diggs, C., Soisson, L., Cummings, J. F., Stewart, A. V., Palmer, D. R., Mahajan, B., Krzych, U., Tornieporth, N., Delchambre, M., Vanhandenhove, M., Ofori-Anyinam, O., Cohen, J., Lyon, J. A., Heppner, D. G. & The MSP-1 Working Group (2006). Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine. Vaccine. 24, 3009-3017.
88. Ogutu, B. R., Apollo, O. J., McKinney, D., Okoth, W., Siangla, J., Dubovsky, F., Tucker, K., Waitumbi, J. N., Diggs, C., Wittes, J., Malkin, E., Leach, A., Soisson, L. A., Milman, J. B., Otieno, L., Holland, C. A., Polhemus, M., Remich, S. A., Ockenhouse, C. F., Cohen, J., Ballou, W. R., Martin, S. K., Angov, E., Stewart, V. A., Lyon, J. A., Heppner Jr, D. G., Withers, M. R. & The MSP-1 Vaccine Working Group (2009). Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in western Kenya. PLoS One, 4, e4708.
89. Okiro, E. A., Hay, S. I., Gikandi, P. W., Sharif, S. K., Noor, A. M., Peshu, N., Marsh, K. & Snow, R. W. (2007). The decline in paediatric malaria admissions on the coast of Kenya. Malaria Journal, 6, 151.
90. Oxford, J. S. (2008). The end of the beginning: vaccines for the next 25 years. Vaccine, 26, 6179-6182.
91. Persson, C., Oliveira, G. A., Sultan, A. A., Bhanot, P., Nussenzweig, V. & Nardin, E. (2002). Cutting edge: a new tool to evaluate human pre-erythrocytic malaria vaccines: rodent parasites bearing a hybrid Plasmodium falciparum circumsporozoite protein. Journal of Immunology, 169, 6681-6685.
92. Pichichero, M. E. (2008). Improving vaccine delivery using novel adjuvant systems. Human Vaccines, 4, 262-270.
93. Pichyangkul, S., Tongtawe, P., Kum-Arb, U., Yongvanitchit, K., Gettayacamin, M., Hollingdale, M. R., Limsalakpetch, A., Stewart, V. A., Lanar, D. E., Dutta, S., Angov, E., Ware, L. A., Bergmann-Leitner, E. S., House, B., Voss, G., Dubois, M. C., Cohen, J. D., Fukuda, M. M., Heppner, D. G. & Miller, R. S. (2009). Evaluation of the safety and immunogenicity of Plasmodium falciparum apical membrane antigen 1, merozoite surface protein 1 or RTS,S vaccines with adjuvant system AS02A administered alone or concurrently in rhesus monkeys. Vaccine, 28, 452-462.
94. Pierce, M. A., Ellis, R. D., Martin, L. B., Malkin, E., Tierney, E., Miura, K., Fay, M. P., Marjason, J., Elliott, S. L., Mullen, G. E., Rausch, K., Zhu, D., Long, C. A. & Miller, L. H. (2010). Phase 1 safety and immunogenicity trial of the Plasmodium falciparum blood-stage malaria vaccine AMA1-C1/ISA 720 in Australian adults. Vaccine, 28, 2236-2242.
95. Pinzon-Charry, A. & Good, M. F. (2008). Malaria vaccines: the case for a whole-organism approach. Expert Opinion on Biological Therapy, 8, 441-448.
96. Pleass, R. J. (2009). Fc-receptors and immunity to malaria: from models to vaccines. Parasite Immunology, 31, 529-538.
97. Polhemus, M. E., Magill, A. J., Cummings, J. F., Kester, K. E., Ockenhouse, C. F., Lanar, D. E., Dutta, S., Barbosa, A., Soisson, L., Diggs, C. L., Robinson, S. A., Haynes, J. D., Stewart, V. A., Ware, L. A., Brando, C., Krzych, U., Bowden, R. A., Cohen, J. D., Dubois, M. C., Ofori-Anyinam, O., De-Kock, E., Ballou, W. R. & Heppner Jr, D. G. (2007). Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naive adults at the Walter Reed Army Institute of Research. Vaccine, 25, 4203-4212.
98. Pombo, D. J., Lawrence, G., Hirunpetcharat, C., Rzepczyk, C., Bryden, M., Cloonan, N., Anderson, K., Mahakunkijcharoen, Y., Martin, L. B., Wilson, D., Elliott, S., Elliott, S., Eisen, D. P., Weinberg, J. B., Saul, A. & Good, M. F. (2002). Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet, 360, 610-617.
99. Ramjanee, S., Robertson, J. S., Franke-Fayard, B., Sinha, R., Waters, A. P., Janse, C. J., Wu, Y., Blagborough, A. M., Saul, A. & Sinden, R. E. (2007). The use of transgenic Plasmodium berghei expressing the Plasmodium vivax antigen P25 to determine the transmission-blocking activity of sera from malaria vaccine trials. Vaccine, 25, 886-894.
100. Reed, S. G., Bertholet, S., Coler, R. N. & Friede, M. (2009). New horizons in adjuvants for vaccine development. Trends in Immunology, 30, 23-32.
101. Remarque, E. J., Faber, B. W., Kocken, C. H. M. & Thomas, A. W. (2008). Apical membrane antigen 1: a malaria vaccine candidate in review. Trends in Parasitology, 24, 74-84.
102. Rerks-Ngarm, S., Pitisuttithum, P., Nitayaphan, S., Kaewkungwal, J., Chiu, J., Paris, R., Premsri, N., Namwat, C., de Souza, M., Adams, E., Benenson, M., Gurunathan, S., Tartaglia, J., McNeil, J. G., Francis, D. P., Stablein, D., Birx, D. L., Chunsuttiwat, S., Khamboonruang, C., Thongcharoen, P., Robb, M. L., Michael, N. L., Kunasol, P. & Kim, J. H. (2009). Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. New England Journal of Medicine, 361, 2209-2220.
103. Reyes-Sandoval, A., Pearson, F. E., Todryk, S. & Ewer, K. (2009). Potency assays for novel T-cell-inducing vaccines against malaria. Current Opinion in Molecular Therapeutics, 11, 72-80.
104. Roestenberg, M., Remarque, E., de Jonge, E., Hermsen, R., Blythman, H., Leroy, O., Imoukhuede, E., Jepsen, S., Ofori-Anyinam, O., Faber, B., Kocken, C. H. M., Arnold, M., Walraven, V., Teelen, K., Roeffen, W., de Mast, Q., Ballou, W. R., Cohen, J., Dubois, M. C., Ascarateil, S., van der Ven, A., Thomas, A. & Sauerwein, R. (2008). Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02. PLoS One, 3, e3960.
105. Roestenberg, M., McCall, M., Hopman, J., Wiersma, J., Luty, A. J. F., van Gemert, G. J., van de Vegte-Bolmer, M., van Schaijk, B., Teelen, K., Arens, T., Spaarman, L., de Mast, Q., Roeffen, W., Snounou, G., Renia, L., van der Ven, A., Hermsen, C. C. & Sauerwein, R. (2009). Protection against a malaria challenge by sporozoite inoculation. New England Journal of Medicine, 361, 468-477.
106. Sagara, I., Dicko, A., Ellis, R. D., Fay, M. P., Diawara, S. I., Assadou, M. H., Sissoko, M. S., Kone, M., Diallo, A. I., Saye, R., Guindo, M. A., Kante, O., Niambele, M. B., Miura, K., Mullen, G. E. D., Pierce, M., Martin, L. B., Dolo, A., Diallo, D. A., Doumbo, O. K., Miller, L. H. & Saul, A. (2009a). A randomized controlled Phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali. Vaccine, 27, 3090-3098.
107. Sagara, I., Ellis, R. D., Dicko, A., Niambele, M. B., Kamate, B., Guindo, O., Sissoko, M. S., Fay, M. P., Guindo, M. A., Kante, O., Saye, R., Miura, K., Long, C., Mullen, G. E. D., Pierce, M., Martin, L. B., Rausch, K., Dolo, A., Diallo, D. A., Miller, L. H. & Doumbo, O. K. (2009b). A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/AlhydrogelzCPG 7909 vaccine for Plasmodium falciparum malaria in semiimmune Malian adults. Vaccine, 27, 7292-7298.
108. Sanderson, F., Andrews, L., Douglas, A. D., Hunt-Cooke, A., Bejon, P. & Hill, A. V. S. (2008). Blood-stage challenge for malaria vaccine efficacy trials: a pilot study with discussion of safety and potential value. American Journal of Tropical Medicine and Hygiene, 78, 878-883.
109. Saul, A., Lawrence, G., Smillie, A., Rzepczyk, C. M., Reed, C., Taylor, D., Anderson, K., Stowers, A., Kemp, R., Allworth, A., Anders, R. F., Brown, G. V., Pye, D., Schoofs, P., Irving, D. O., Dyer, S. L., Woodrow, G. C., Briggs, W. R., Reber, R. & Sturchler, D. (1999). Human Phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant. Vaccine, 17, 3145-3159.
110. Saul, A., Lawrence, G., Allworth, A., Elliott, S., Anderson, K., Rzepczyk, C., Martin, L. B., Taylor, D., Eisen, D. P., Irving, D. O., Pye, D., Crewther, P. E., Hodder, A. N., Murphy, V. J. & Anders, R. F. (2005). A human Phase 1 vaccine clinical trial of the Plasmodium falciparum malaria vaccine candidate apical membrane antigen 1 in Montanide ISA720 adjuvant. Vaccine, 23, 3076-3083. (Pubitemid 40462448)
111. Schofield, L., Hewitt, M. C., Evans, K., Siomos, M.-A. & Seeberger, P. H. (2002). Synthetic GPI as a candidate anti-toxic vaccine in a model of malaria. Nature, 418, 785-789.
112. Silvie, O., Franetich, J.-F., Charrin, S., Mueller, M. S., Siau, A., Bodescot, M., Rubinstein, E., Hannoun, L., Charoenvit, Y., Kocken, C. H., Thomas, A. W., van Gemert, G.-J., Sauerwein, R. W., Blackman, M. J., Anders, R. F., Pluschke, G. & Mazier, D. (2004). A role for apical membrane antigen 1 during invasion of hepatocytes by Plasmodium falciparum sporozoites. Journal of Biological Chemistry, 279, 9490-9496.
113. Singh, S., Alam, M. M., Pal-Bhowmick, I., Brzostowski, J. A. & Chitnis, C. E. (2010). Distinct external signals trigger sequential release of apical organelles during erythrocyte invasion by malaria parasites. PLoS Pathogens, 6, e1000746.
114. Sirima, S. B., Nébié, I., Ouédraogo, A., Tiono, A. B., Konaté, A. T., Gansané, A., Dermé, A. I., Diarra, A., Ouédraogo, A., Soulama, I., Cuzzin-Ouattara, N., Cousens, S. & Leroy, O. (2007). Safety and immunogenicity of the Plasmodium falciparum merozoite surface protein-3 long synthetic peptide (MSP3-LSP) malaria vaccine in healthy, semiimmune adult males in Burkina Faso, West Africa. Vaccine, 25, 2723-2732.
115. Sirima, S. B., Tiono, A. B., Ouédraogo, A., Diarra, A., Ouédraogo, A. L., Yaro, J. B., Ouédraogo, E., Gansané, A., Bougouma, E. C., Konaté, A. T., Kaboré, Y., Traoré, A., Roma, C., Soulama, I., Luty, A. J., Cousens, S. & Nébié, I. (2009). Safety and immunogenicity of the malaria vaccine candidate MSP3 long synthetic peptide in 12-24 months-old Burkinabe children. PLoS One, 4, e7549.
116. Spring, M. D., Cummings, J. F., Ockenhouse, C. F., Dutta, S., Reidler, R., Angov, E., Bergmann-Leitner, E., Stewart, V. A., Bittner, S., Juompan, L., Kortepeter, M. G., Nielsen, R., Krzych, U., Tierney, E., Ware, L. A., Dowler, M., Hermsen, C. C., Sauerwein, R. W., de Vlas, S. J., Ofori-Anyinam, O., Lanar, D. E., Williams, J. L., Kester, K. E., Tucker, K., Shi, M., Malkin, E., Long, C., Diggs, C. L., Soisson, L., Dubois, M.-C., Ballou, W. R., Cohen, J. & Heppner Jr, D. G. (2009). Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A. PLoS One, 4, e5254.
117. Stahl, H. D., Bianco, A. E., Crewther, P. E., Anders, R. F., Kyne, A. P., Coppel, R. L., Mitchell, G. F., Kemp, D. J. & Brown, G. V. (1986). Sorting large numbers of clones expressing Plasmodium falciparum antigens in Escherichia coli by differential antibody screening. Molecular Biology and Medicine, 3, 351-368.
118. Stoute, J. A., Gombe, J., Withers, M. R., Siangla, J., McKinney, D., Onyango, M., Cummings, J. F., Milman, J., Tucker, K., Soisson, L., Stewart, V. A., Lyon, J. A., Angov, E., Leach, A., Cohen, J., Kester, K. E., Ockenhouse, C. F., Holland, C. A., Diggs, C. L., Wittes, J. & Heppner Jr, D. G. (2007). Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya. Vaccine, 25, 176-184.
119. Suhrbier, A., Holder, A. A., Wiser, M. F., Nicholas, J. & Sinden, R. E. (1989). Expression of the precursor of the major merozoite surface antigens during the hepatic stage of malaria. American Journal of Tropical Medicine and Hygiene, 40, 351-355.
120. Szarfman, A., Walliker, D., McBride, J. S., Lyon, J. A., Quakyi, I. A. & Carter, R. (1988). Allelic forms of gp195, a major blood-stage antigen of Plasmodium falciparum, are expressed in liver stages. Journal of Immunology, 167, 231-236.
121. Tebo, A. E., Kremsner, P. G. & Luty, A. J. F. (2002). Fcc receptor-mediated phagocytosis of Plasmodium falciparum-infected erythrocytes in vitro. Clinical and Experimental Immunology, 130, 300-306.
122. Theisen, M., Soe, S., Brunstedt, K., Follmann, F., Bredmose, L., Israelsen, H., Madsen, S. M. & Druilhe, P. (2004). A Plasmodium falciparum GLURP-MSP3 chimeric protein; expression in Lactococcus lactis, immunogenicity and induction of biologically active antibodies. Vaccine, 22, 1188-1198.
123. Thera, M. A., Doumbo, O. K., Coulibaly, D., Diallo, D. A., Sagara, I., Dicko, A., Diemert, D. J., Heppner Jr, D. G., Stewart, V. A., Angov, E., Soisson, L., Leach, A., Tucker, K., Lyke, K. E. & Plowe, C. V. (2006). Safety and allele-specific immunogenicity of a malaria vaccine in Malian adults: results of a Phase I randomized trial. PLoS Clinical Trials, 1, e34.
124. Thera, M. A., Doumbo, O. K., Coulibaly, D., Diallo, D. A., Kone, A. K., Guindo, A. B., Traore, K., Dicko, A., Sagara, I., Sissoko, M. S., Baby, M., Sissoko, M., Diarra, I., Niangaly, A., Dolo, A., Daou, M., Diawara, S. I., Heppner, D. G., Stewart, V. A., Angov, E., Bergmann-Leitner, E. S., Lanar, D. E., Dutta, S., Soisson, L., Diggs, C. L., Leach, A., Owusu, A., Dubois, M. C., Cohen, J., Nixon, J. N., Gregson, A., Takala, S. L., Lyke, K. E. & Plowe, C. V. (2008). Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a Phase 1 randomized controlled trial. PLoS One, 3, e1465.
125. Thompson, F. M., Porter, D. W., Okitsu, S. L., Westerfeld, N., Vogel, D., Todryk, S., Poulton, I., Correa, S., Hutchings, C., Berthoud, T., Dunachie, S., Andrews, L., Williams, J. L., Sinden, R., Gilbert, S. C., Pluschke, G., Zurbriggen, R. & Hill, A. V. S. (2008). Evidence of blood stage efficacy with a virosomal malaria vaccine in a Phase IIa clinical trial. PLoS One, 3, e1493.
126. Traore, B., Koné, Y., Doumbo, S., Doumtabé, D., Traoré, A., Crompton, P. D., Mircetic, M., Huang, C.-Y., Kayentao, K., Dicko, A., Sagara, I., Ellis, R. D., Miura, K., Guindo, A., Miller, L. H., Doumbo, O. K. & Pierce, S. K. (2009). The TLR9 agonist CpG fails to enhance the acquisition of Plasmodium falciparum-specific memory B cells in semi-immune adults in Mali. Vaccine, 27, 7299-7303.
127. Treeck, M., Zacherl, S., Herrmann, S., Cabrera, A., Kono, M., Struck, N. S., Engelberg, K., Haase, S., Frischknecht, F., Miura, K., Spielmann, T. & Gilberger, T. W. (2009). Functional analysis of the leading malaria vaccine candidate AMA-1 reveals an essential role for the cytoplasmic domain in the invasion process. PLoS Pathogens, 5, e1000322.
128. Triglia, T., Healer, J., Caruana, S. R., Hodder, A. N., Anders, R. F., Crabb, B. S. & Cowman, A. F. (2000). Apical membrane antigen 1 plays a central role in erythrocyte invasion by Plasmodium species. Molecular Microbiology, 38, 706-718.
129. Van der Heyde, H. C., Huszar, D., Woodhouse, C., Manning, D. D. & Weidanz, W. P. (1994). The resolution of acute malaria in a definitive model of B cell deficiency, the JHD mouse. Journal of Immunology, 152, 4557-4562.
130. Vargas-Serrato, E., Barnwell, J. W., Ingravallo, P., Perler, F. B. & Galinski, M. R. (2002). Merozoite surface protein-9 of Plasmodium vivax and related simian malaria parasites is orthologous to p101/ ABRA of P. falciparum. Molecular and Biochemical Parasitology, 120, 41-52.
131. Wang, Q., Brown, S., Roos, D. S., Nussenzweig, V. & Bhanot, P. (2004). Transcriptome of axenic liver stages of Plasmodium yoelii. Molecular and Biochemical Parasitology, 137, 161-168.
132. Webster, D. P., Dunachie, S., Vuola, J. M., Berthoud, T., Keating, S., Laidlaw, S. M., McConkey, S. J., Poulton, I., Andrews, L., Andersen, R. F., Bejon, P., Butcher, G., Sinden, R., Skinner, M. A., Gilbert, S. C. & Hill, A. V. S. (2005). Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proceedings of the National Academy of Sciences of the United States of America, 102, 4836-4841.
133. Weiss, G. E., Crompton, P. D., Li, S., Walsh, L. A., Moir, S., Traore, B., Kayentao, K., Ongoiba, A., Doumbo, O. K. & Pierce, S. K. (2009). Atypical memory B cells are greatly expanded in individuals living in a malaria-endemic area. Journal of Immunology, 183, 2176-2182.
134. Wipasa, J., Hirunpetcharat, C., Mahakunkijcharoen, Y., Xu, H., Elliott, S. & Good, M. F. (2002). Identification of T cell epitopes on the 33-kDa fragment of Plasmodium yoelii merozoite surface protein 1 and their antibody-independent protective role in immunity to blood stage malaria. Journal of Immunology, 169, 944-951.
135. World Health Organization (2008). World Malaria Report 2008. Document WHO/HTM/GMP/2008.1. Geneva: WHO.
136. Wykes, M. N., Zhou, Y.-H., Liu, X. Q. & Good, M. F. (2005). Plasmodium yoelii can ablate vaccine-induced long-term protection in mice. Journal of Immunology, 175, 2510-2516.
137. Xu, H., Hodder, A. N., Yan, H., Crewther, P. E., Anders, R. F. & Good, M. F. (2000). CD4z T cells acting independently of antibody contribute to protective immunity to Plasmodium chabaudi infection after apical membrane antigen 1 immunization. Journal of Immunology, 165, 389-396.
138. Yoneto, T., Waki, S., Takai, T., Tagawa, Y., Iwakura, Y., Mizuguchi, J., Nariuchi, H. & Yoshimoto, T. (2001). A critical role of Fc receptor-mediated antibody-dependent phagocytosis in the host resistance to blood-stage Plasmodium berghei XAT infection. Journal of Immunology, 166, 6236-6241.